title: Distinct evolutionary paths to TKI resistance in NSCLC.
authors.affiliation: a Massachusetts General Hospital Cancer Center , Charlestown , MA , USA.|b Department of Medicine , Harvard Medical School , Boston , MA , USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Niederst
authors.affiliation: a Massachusetts General Hospital Cancer Center , Charlestown , MA , USA.|b Department of Medicine , Harvard Medical School , Boston , MA , USA.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Engelman
authors.affiliation: a Massachusetts General Hospital Cancer Center , Charlestown , MA , USA.|b Department of Medicine , Harvard Medical School , Boston , MA , USA.
authors.forename: Aaron N
authors.initials: AN
authors.lastname: Hata
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018365:Neoplasm, Residual / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors